AbbVie
Shire buys rare-disease firm NPS Pharma
January 12, 2015Sales and Marketing AbbVie, Shire, gattex, natpara, nps, nps pharma
Shire is to acquire rare diseases firm NPS Pharma to enhance its profile following the collapse of its deal with …
Abbvie Hep C drug gains FDA approval
December 22, 2014Sales and Marketing AbbVie, FDA, Gilead, Viekira Pak, dasabuvir, harvoni, hepatitis, hepatits C
Abbvie has gained sign-off for its rival treatment to challenge Gilead’s dominance of the growing market for new hepatitis C …
Mylan shells out $32.5m to cover tax inversion fines
December 11, 2014Sales and Marketing AbbVie, Abbott, Mylan, SEC, bresch, coury
Mylan will pay five of its top executives an early $32.5 million to cover penalties from the company’s plans to …
EMA responds to redaction concerns
November 14, 2014Sales and Marketing AbbVie, EMA, Goldacre, Humira, Rasi, adalimumab, redactions, transparency
The EMA has published a response to European Ombudsman Emily O’Reilly’s questions about some of its trial data redactions. O’Reilly’s …
AbbVie financials beat expectations
October 31, 2014Sales and Marketing AbbVie, Abbott, Creon, Humira, Iopinavir/ritonavir, Kaletra, Q3, Synthroid, levothyroxine, pancrelipase
AbbVie has announced higher-than-expected financial results for the third quarter of 2014, although it continues to rely heavily on blockbuster …
Google X developing diagnosis pill
October 29, 2014Medical Communications, Research and Development, Sales and Marketing AbbVie, Pfizer, calico, diagnosis pill, google, google x, vida, wearables
Google is developing a new pill designed to send microscopic particles into the bloodstream in an effort to identify cancers, …
Shire interim chief financial officer resigns
October 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Shire, james bowling, merger
Shire’s interim chief financial officer James Bowling has left the firm for water company Severn Trent following the collapse of …
AbbVie ditches Shire as tax deal falters
October 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Obama, Shire, US government, tax, tax inversion
Tax rule changes coming from the US government have forced the collapse of a multi-billion dollar deal between Humira manufacturer …
AbbVie reconsiders Shire deal over tax laws
October 15, 2014Medical Communications, Sales and Marketing AbbVie, Abbott, Obama, Shire, US, mergers, tax
AbbVie will reconsider its planned $54.6 billion takeover of Shire in light of new US proposals designed to curb companies …
Mixed response to EMA data transparency plans
October 3, 2014Medical Communications, Research and Development, Sales and Marketing AbbVie, BMJ, Ben Goldacre, EMA, alltrials, transparency
The European Medicines Agency has passed new rules that will mandate pharma to release more of its clinical trial data …
Google’s Calico takes first steps into research
September 12, 2014Medical Communications, Sales and Marketing AbbVie, P7C3, Parkinson's, Parkinson’s, calico, depression, google, motor neurone disease
Google is finally shifting into gear within the health arena as it signs its first research deal to develop a …
Federal Trade Commission sues AbbVie and Teva
September 9, 2014Manufacturing and Production, Sales and Marketing AbbVie, FTC, Teva, androgel, federal trade commission
Authorities in the US claim that AbbVie and Teva filed ‘sham’ lawsuits in a complicated pay-to-delay case for generic forms …
AbbVie and Infinity sign cancer deal
September 4, 2014Research and Development, Sales and Marketing AbbVie, IPI-145, blood cancer, duvelisib, infinity
AbbVie has partnered with US company Infinity Pharmaceuticals to develop and commercialise the latter firm’s blood cancer treatment duvelisib (IPI-145). …
Google partners with AbbVie on ageing
September 4, 2014Medical Communications, Research and Development, Sales and Marketing 23andME, AbbVie, Abbott, Roche, calico, google
Google’s healthcare company Calico has signed its first pharma pact with US firm AbbVie in a deal that could be …
AbbVie/Shire deal under threat from tax laws
August 7, 2014Medical Communications, Sales and Marketing AbbVie, AstraZeneca, Pfizer, Shire, tax inversion
The £32 billion deal between AbbVie and Irish specialist biotech Shire could be under threat from new rules in the …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
